Amneal Pharmaceuticals, Inc. (AMRX)

Market Cap	3.57B
Revenue (ttm)	2.93B
Net Income (ttm)	5.90M
Shares Out	314.36M
EPS (ttm)	0.02
PE Ratio	605.81
Forward PE	13.43
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,268,384
Open	11.66
Previous Close	11.66
Day's Range	11.29 - 11.66
52-Week Range	6.69 - 11.88
Beta	1.38
Analysts	Buy
Price Target	12.67 (+11.43%)
Earnings Date	Oct 30, 2025

About AMRX

Amneal Pharmaceuticals, Inc., a global biopharmaceutical company, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Affordable Medicines, Specialty, and AvKARE. The Affordable Medicines segment offers dosage forms and delivery systems, which include immediate and extended-release oral solids, powders, liquids, sterile injectables, nasal sprays, inhalation and respiratory products, biosimilar products, ophthalm...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2002
• Employees: 8,300
• Stock Exchange: NASDAQ
• Ticker Symbol: AMRX
• Website: https://www.amneal.com

Financial Performance

In 2024, Amneal Pharmaceuticals's revenue was $2.79 billion, an increase of 16.73% compared to the previous year's $2.39 billion. Losses were -$116.89 million, 39.2% more than in 2023.

Analyst Summary

According to 3 analysts, the average rating for AMRX stock is "Buy." The 12-month stock price target is $12.67, which is an increase of 11.43% from the latest price.

Price Target

$12.67

(11.43% upside)

Analyst Consensus: Buy